Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amneal Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces Move to Nasdaq
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Third Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Third Quarter 2023 Results on November 7, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives First Product Approval in China
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Second Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Second Quarter 2023 Results on August 4, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives U.S. FDA Complete Response Letter for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at the 2023 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.